To compare pramipexole to escitalopram in the treatment of major depressive disorder in people living with HIV.
To evaluate the Season 2 (2024/ 2025) immune response of children who received nirsevimab in the 2023-2024 season (Season 1) compared to the immune response of children who did not receive nirsevimab in Season 1 and To compare the frequency and severity of illness in Season 2 between children who received nirsevimab in Season 1 to children who did not receive nirsevimab in Season 1 as assessed by ...
This study will evaluate how well, how safe, and how long-lasting a treatment called CAB LA + RPV LA is for people with HIV who still have detectable virus levels even though they are taking oral ART. The study will also consider feedback from patients on their experience with this treatment.
The purpose of this study is to see if an experimental vaccine called CH505 TF chTrimer is safe and well tolerated in people living with human immunodeficiency virus (HIV) and to see if it will help the body's immune system respond to HIV.
The primary objective of the study is to evaluate the efficacy of switching to oral weekly ISL/LEN tablet regimen versus continuing standard of care in virologically suppressed PWH at Week 48.
This study will test whether a single dose of antibodies can help prevent COVID-19 from getting worse in high-risk adult patients recently diagnosed with COVID-19.
This study wants to see if gut problems are worse in HIV+ men that have sex with men that have metabolic syndrome compared those without metabolic syndrome.
To evaluate the health and wellbeing of women living with HIV of reproductive age utilizing innovative epidemiologic study designs and cost-effective methods for enrollment, follow-up and data collection
To find out if bNAbs, VRC07-523LS and PGT121.414.LS, are safe for administration with ART. To evaluate if the bNAbs are effective at keeping HIV from reproducing. It is necessary to stop taking ART after receiving the bNAbs or placebos for bNAbs. This is referred to as an ATI (analytical treatment interruption).
The purpose of this study is to determine the best combination of antiretroviral therapy for transgender women (TW) living with HIV who take feminization hormonal therapy (FHT). All participants will receive FHT. The study will determine if TW remain undetectable while receiving FHT for 48 weeks. Additionally, it will assess if hormone levels change based on the type of HIV medication taken.
The study aims to assess safety and tolerability of oral toll-like receptor (TLR) 8 agonist Selgantolimod (SLGN) administered for 24 weeks in participants with both CHB and HIV who have been receiving suppressive antiviral therapy for both viruses for ≥5 years and have qHBsAg level >1000 (3 log10) IU/mL at screening. The study will also evaluate if TLR8 stimulation with SLGN will reduce hepatitis ...
